Certara Selected by the European Medicines Agency to Provide Real World Solutions for Critical Regulatory Decisions
Princeton, N.J., 2022 年 3 月 17 日 -- Certara, Inc. today announced a four-year, framework service contract…
Certara2022 年 3 月 17 日
The Challenging Road to Developing an Integrated Platform for Drug Discovery and Precision Medicine Using the Power of Pharmacometrics
We have often seen Dr. Hwi-yeol (Thomas) Yun, Associate Professor/Adjunct Professor at the College of…
Certara2022 年 2 月 7 日
Improved Workflow and Expanded functionality of RsNLME v1.1
R Speaks NLME (RsNLME) is a collection of R packages and companion RShiny apps that…
Certara2022 年 1 月 31 日
Don’t Forget About Safety! How to Assess Drug Candidate Safety in Early Clinical Development
This blog will reflect on 3 things drug developers should pay attention to regarding safety…
Certara2022 年 1 月 24 日
Getting Results Faster – Supporting Physicians and Pharmacists with Biosimulation Technologies
Certara’s Phoenix biosimulation software platform is widely used for non-compartmental analysis (NCA), pharmacokinetic/pharmacodynamic (PK/PD), and…
Certara2022 年 1 月 19 日
R Speaks NLME (RsNLME) Overview
This recording shows an overall review of RsNLME using Pirana and an extensive explanation on…
Certara2022 年 1 月 19 日
What Oncology Drug Developers Should Expect from the FDA’s Project Optimus
一直以来，肿瘤药物的剂量策略都以最大耐受剂量为重点。This…
Certara2022 年 1 月 13 日
PBPK Modeling of Antibody-Drug Conjugates – Concept and Application
Antibody-Drug Conjugates (ADCs) can be an ideal drug treatment for cancer because they deliver a…
Certara2022 年 1 月 13 日
